Infectious Disease
RSV
More in RSV
While all adults age 75 and up are eligible, here's who's considered high risk in the 60-74 group
Nov 11, 2024

"Remarkable" how closely effectiveness in real-world setting matches clinical trial efficacy
Nov 11, 2024

Another vaccine option, updated ACIP recommendations, and data on a new monoclonal antibody
Nov 08, 2024

Decision was based on need for RSV protection in younger people with chronic conditions
Oct 23, 2024

Clesrovimab reduced severe disease, hospitalizations in preterm and term healthy infants
Oct 19, 2024

Continuing Medical Education
1.50
CME Credits